Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-26T14:11:27.235Z Has data issue: false hasContentIssue false

HTLV-1 Associated Myelopathy in Canada

Published online by Cambridge University Press:  18 September 2015

Christopher Power
Affiliation:
Department of Clinical Neurological Sciences, and Robarts Research Institute, University of Western Ontario, University Hospital, London and the Montreal Neurological Hospital, Montreal
Brian G. Weinshenker
Affiliation:
Department of Clinical Neurological Sciences, and Robarts Research Institute, University of Western Ontario, University Hospital, London and the Montreal Neurological Hospital, Montreal
Gregory A. Dekaban
Affiliation:
Department of Clinical Neurological Sciences, and Robarts Research Institute, University of Western Ontario, University Hospital, London and the Montreal Neurological Hospital, Montreal
G.C. Ebers
Affiliation:
Department of Clinical Neurological Sciences, and Robarts Research Institute, University of Western Ontario, University Hospital, London and the Montreal Neurological Hospital, Montreal
Gordon S. Francis
Affiliation:
Department of Clinical Neurological Sciences, and Robarts Research Institute, University of Western Ontario, University Hospital, London and the Montreal Neurological Hospital, Montreal
George P.A. Rice*
Affiliation:
Department of Clinical Neurological Sciences, and Robarts Research Institute, University of Western Ontario, University Hospital, London and the Montreal Neurological Hospital, Montreal
*
Department of Clinical Neurological Sciences, University of Western Ontario, University Hospital, 339 Windermere Rd., London, Ontario, Canada N6A 5A5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We report the clinical and laboratory findings of six Canadian patients with progressive myelopathy associated with HTLV-1 infection. The diagnosis was suspected on clinical grounds and supported by serological studies and positive gene amplification. Only five had emigrated from an area endemic for HTLV-1 infection. Tropical spastic paraparesis should be considered in all patients with myelopathy, even those without standard serological markers of HTLV-1 infection. The pathogenesis of this condition and the serological and molecular biological means by which this diagnosis can be made are reviewed.

Type
Original Articles
Copyright
Copyright © Canadian Neurological Sciences Federation 1989

References

REFERENCES

1.Cruickshank, EK. A neuropathic syndrome of uncertain origin: a review of 100 cases. West Indian Med J 1956; 5: 147158.Google ScholarPubMed
2.Gessain, A, Barin, F, Vernant, JC, et al. Antibodies to human T lym-photropic virus type I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407410.CrossRefGoogle Scholar
3.Roman, GC, Roman, LN, Spencer, PS, Schoenberg, BS. Tropical spastic paraparesis: a neuroepidemiological study in Colombia. Ann Neurol 1985; 17: 361365.CrossRefGoogle ScholarPubMed
4.Roman, GC, Spencer, PS, Schoenberg, BS, et al. Tropical spastic paraparesis in the Seychelles Islands: a clinical and case control neuroepidemiologic study. Neurology 1987; 37: 13231328.CrossRefGoogle ScholarPubMed
5.Roman, GC. The Neuroepidemiology of Tropical Spastic Paraparesis. Ann Neurol 1988; 23 (supp): S113-S120.CrossRefGoogle ScholarPubMed
6.Osarne, M, Matsamuto, M, Usuka, K, et al. Chronic progressive myelopathy associated with elevated antibodies to HTLV-1 and adult T-cell leukemia-like cells. Ann Neurol 1987; 21: 117122.Google Scholar
7.Jacobson, S, Raine, CS, Mingioli, ES, MacFarlin, D. Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature 1988; 331: 540543.CrossRefGoogle ScholarPubMed
8.Bhagavati, S, Ehrlich, G, Kula, R, et al. Detection of human T-cell lymphoma/leukemia virus type I DNA and antigen in spinal fluid and blood of patients with chronic progressive myelopathy. N Engl J Med 1988; 318: 11411147.CrossRefGoogle ScholarPubMed
9.Weinshenker, BG, Rice, GPA. Retrovirus diseases of the nervous system. In: Demyelinating Diseases of the Nervous System. Ed. S Kim Plenum (in press).Google Scholar
10.Canaani, E, Aaronson, SA. Restriction enzyme analysis of mouse cellular type-C viral DNA: emergence of new viral sequences in spontaneous AKR/J lymphomas. Proc Natl Acad Sci USA 1974; 77: 55795783.Google Scholar
11.Seiki, M, Seisuke, H, Hirayama, Y, Yoshida, M. HTLV-1 virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Nat Acad Sci 1983; 80: 36183622.CrossRefGoogle Scholar
12.Clark, P, Lin, HC, Wilcox, G. Ultraviolet imaging: A simple method for detecting nucleic acids in preparative gels. Analytical Biochem 1982; 124: 1422.Google Scholar
13.Saiki, R, Gelfand, D, Stoffel, S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487494.CrossRefGoogle ScholarPubMed
14.Southern, EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis on nitro-cellulose. J Mol Biol 1975; 38: 503517.CrossRefGoogle Scholar
15.Goudreau, G, Karpati, G, Carpenter, S. Inflammatory Myopathy in Association with Chronic Myelopathy in HTLV-1 Seropositive Patients. Neurology 1988; 38 (suppl): 206.Google Scholar
16.Vernant, JC, Maurs, L, Gessain, A, et al. Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical sero-epidemiological study of 25 cases. Ann Neurol 1987; 21: 123130.CrossRefGoogle Scholar
17.Osarne, M, Usuku, K, Izumo, S, et al. HTLV-1 associated myelopathy: a new clinical entity. Lancet 1986; 1: 10311032.Google Scholar
18.Williams, AE, Fang, CE, Slamon, DJet al. Seroprevalence and epi-demiological correlates of HTLV-1 Infection in U.S. Blood Donors. Science 1988; 240: 643646.CrossRefGoogle Scholar
19.Alvarez, G, Cardenas, M. Multiple sclerosis following optic neuritis in Chile. J Neurol Neurosurg Psychiatry 1989; 54: 115117.CrossRefGoogle Scholar
20.Loche, M, Mach, B. Identification of HIV-infected seronegative individuals by a diagnostic test based on hybridization to amplified viral DNA. Lancet 1988; 2: 418420.CrossRefGoogle ScholarPubMed
21.Saida, T. HTLV-1 associated myelopathy in Japan. International Symposium on Retrovirus in multiple sclerosis and related disease. Copenhagen.Google Scholar
22.Bartholomew, C, Cleghorn, F, Wavenay, C, et al. HTLV-1 and Tropical Spastic Paraparesis 1986. Lancet; 2: 910.Google Scholar
23.Usuko, K, Sonoda, S, Osame, M, et al. HLA haplotype linked high immune responsiveness against HTLV-1 in HTLV-1 Associated Myelopathy: comparison with Adult T-cell leukemic/lymphoma. Ann Neurol 1988; 23 (suppl): 5143–159.Google Scholar
24.Koprowski, H, DeFreitas, EC, Harper, ME, et al. Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature 1985; 318: 154160.CrossRefGoogle ScholarPubMed
25.Rice, GPA, Armstrong, HA, Bulmer, DE, et al. Absence of antibody to HTLV-1 and III in sera of Canadian patients with multiple sclerosis and chronic myelopathy. Ann Neurol 1986; 20: 533534.CrossRefGoogle Scholar
26.Robertson, WB, Cruickshank, EK. Jamaican (tropical) myeloneuropathy. In: Minkler, 3 ed. Pathology of the Nervous System. Vol. 3 New York: McGraw, 1972; 24662476.Google Scholar
27.Gessain, A, et al. Intrathecal synthesis of antibodies to Human T Lymphotropic Virus Type I and the presence of IgG oligoclonal bands in cerebrospinal fluid of patients with endemic Tropical Spastic Paraparesis. J Infect Dis 1988; 157(6): 12261234.CrossRefGoogle ScholarPubMed